Opdivo Superior to Chemotherapy in Patients with Advanced Esophageal Cancer, Trial Shows
Categories
Opdivo demonstrated a significant improvement over chemotherapy, with a 23% reduction in risk of death and a 2.5-month improvement in the median time patients survived, compared to those on chemotherapy. Opdivo’s safety profile was consistent with that reported previously.